HC Wainwright Has Positive View of REGENXBIO FY2024 Earnings

REGENXBIO Inc. (NASDAQ:RGNX) – HC Wainwright increased their FY2024 EPS estimates for shares of REGENXBIO in a report issued on Thursday, November 7th. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will earn ($4.92) per share for the year, up from their previous forecast of ($4.99). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.77) per share. HC Wainwright also issued estimates for REGENXBIO’s Q4 2024 earnings at ($1.33) EPS, Q1 2025 earnings at ($1.35) EPS, Q2 2025 earnings at $2.65 EPS, Q3 2025 earnings at ($1.34) EPS, Q4 2025 earnings at ($1.34) EPS and FY2025 earnings at ($1.39) EPS.

A number of other equities analysts also recently issued reports on RGNX. Raymond James reiterated an “outperform” rating and set a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th. Barclays reduced their price target on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Finally, Chardan Capital restated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a report on Tuesday, October 22nd. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, REGENXBIO presently has a consensus rating of “Moderate Buy” and an average target price of $35.55.

REGENXBIO Trading Up 3.6 %

REGENXBIO stock opened at $11.56 on Monday. The firm has a market cap of $572.68 million, a PE ratio of -2.30 and a beta of 1.23. The stock’s 50 day simple moving average is $10.57 and its two-hundred day simple moving average is $12.41. REGENXBIO has a 12 month low of $8.53 and a 12 month high of $28.80.

Insider Buying and Selling at REGENXBIO

In related news, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the transaction, the director now owns 11,286 shares in the company, valued at approximately $114,101.46. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 13.13% of the company’s stock.

Hedge Funds Weigh In On REGENXBIO

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. nVerses Capital LLC grew its holdings in shares of REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 2,200 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in REGENXBIO in the first quarter valued at approximately $56,000. Headlands Technologies LLC grew its position in shares of REGENXBIO by 276.8% during the first quarter. Headlands Technologies LLC now owns 3,828 shares of the biotechnology company’s stock worth $81,000 after acquiring an additional 2,812 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 3,720 shares during the period. Finally, Diversified Trust Co purchased a new stake in REGENXBIO in the 2nd quarter valued at $121,000. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.